<SEC-DOCUMENT>0001213900-26-043795.txt : 20260415
<SEC-HEADER>0001213900-26-043795.hdr.sgml : 20260415
<ACCEPTANCE-DATETIME>20260415083120
ACCESSION NUMBER:		0001213900-26-043795
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20260415
DATE AS OF CHANGE:		20260415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284606
		FILM NUMBER:		26862613

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea028633402-424b3_kazia.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-284606</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(to Prospectus dated December 22, 2025) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>266,666 American Depositary Shares representing
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>133,333,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ordinary Shares </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea028633402_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement is being filed to update and supplement
the information contained in the prospectus dated December 22, 2025 (the &ldquo;Prospectus&rdquo;), which forms a part of our Registration
Statement on Form F-1 (Registration No. 333-284606), as amended, with the information contained in our current report on Form 6-K, furnished
to the Securities and Exchange Commission on April 15, 2026 (the &ldquo;April 15, 2026 Form 6-K&rdquo;). Accordingly, we have attached
the April 15, 2026 Form 6-K to this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement updates and supplements the information
in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including
any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any
inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The ADSs are listed on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;)
under the symbol &ldquo;KZIA.&rdquo; On April 14, 2026, the last reported sale price of the ADSs on Nasdaq was $9.46 per ADS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk. See
&ldquo;Risk Factors&rdquo; beginning on page 9 of the Prospectus and the &ldquo;Risk Factors&rdquo; in &ldquo;Item 3. Key Information-D.
Risk Factors&rdquo; of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in
any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus
supplement. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement is April
15, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of April 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 000-29962</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Limited.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three International Towers Level 24 300 Barangaroo
Avenue Sydney NSW 2000 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746; <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS FORM 6-K REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Entry into Employment Agreement with Chief Scientific Officer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This report on Form 6-K (the &ldquo;Report&rdquo;) contains information
regarding the entry into a material employment agreement by Kazia Therapeutics Limited (the &ldquo;Company&rdquo;). On April 10, 2026,
the Company entered into an Employment Agreement (the &ldquo;Agreement&rdquo;) with Dr. Sudha Rao, pursuant to which Dr. Rao will serve
as the Company&rsquo;s Chief Scientific Officer (&ldquo;CSO&rdquo;), effective April 13, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Agreement, Dr. Rao will serve as Chief
Scientific Officer on a part-time basis (three days per week) and will receive an annual base salary of AUD$325,000. Dr. Rao is
eligible to receive an annual performance bonus with a target of 40% of her base salary, subject to the achievement of performance
objectives determined by the Company&rsquo;s Board of Directors. The Agreement also provides for a grant of options to acquire
250,000 American Depositary Shares (&ldquo;ADS&rdquo;) of the Company, subject to approval by the Company&rsquo;s Board of
Directors, with one-third vesting upon commencement of employment and the remaining two-thirds vesting in two equal annual
installments on the first and second anniversaries of the commencement date. The Agreement permits Dr. Rao to maintain concurrent
employment with QIMR Berghofer Medical Research Institute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Agreement does not purport to be complete
and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 10.1 to this Report and is
incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Press Release</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is furnishing with this Report on Form 6-K a press release announcing the appointment of Dr. Sudha Rao as Chief Scientific Officer,
dated April </FONT>15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, 2026, as Exhibit 99.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Incorporation by Reference</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby incorporates by reference the information contained
herein, including Exhibits 10.1 and 99.1, except for the quotes of Dr. John Friend, Chief Executive Officer of the Company, contained
in Exhibit 99.1, into the Company&rsquo;s registration statements on Form F-3 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000119312523296811/d866423df3.htm">333-276091</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000119312524213396/d867638df3.htm">333-281937</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000121390026029366/ea0281732-f3_kazia.htm">333-294392</A>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby incorporates by reference the information contained
under the heading &ldquo;Departure of Director&rdquo; in the Company&rsquo;s report on Form 6-K furnished with the Securities and Exchange
Commission on March 31, 2026, but excluding any other information contained in such report, including Exhibits 99.1 and 99.2 thereto,
into the Company&rsquo;s registration statements on Form F-3 (File Nos. <A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000119312523296811/d866423df3.htm">333-276091</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000119312524213396/d867638df3.htm">333-281937</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000121390026029366/ea0281732-f3_kazia.htm">333-294392</A>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#ab_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated as of April 10, 2026, by and between Kazia Therapeutics Limited and Dr. Sudha Rao.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#ab_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated April 15, 2026.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kazia Therapeutics Limited.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Friend</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Friend</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April </FONT>15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><B><A NAME="ab_001"></A>Exhibit
10.1</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><IMG SRC="ea028633402_ex10-1img1.jpg" ALT=""><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="margin: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">February 23, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Dr Sudha Rao</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">14 Captains Court,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Raby Bay</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Cleveland QLD 4164</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Dear Sudha,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: center; text-indent: 0in">Offer of Employment
with Kazia Therapeutics Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">On behalf of Kazia Therapeutics Limited, I am
pleased to offer you the position of Chief Scientific Officer. We look forward to welcoming you as a colleague.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">The terms of the position are as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Position</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Particulars</U>. Your position, place of work,
and commencement date will be as described in Attachment 1 of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Employer</U>. Your employer will be Kazia Therapeutics
Limited (Company/Kazia), a company incorporated in the State of New South Wales, Australia. Kazia reserves the right to assign your employment
to other consolidated corporate entities within its group at its sole discretion, provided that the role does not compete with the 12
Month Priority Project Plan that the Employee has with its other employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Obligation to Best Efforts</U>. You agree that
you will, at all times, loyally and conscientiously perform all the duties and obligations associated with this role to the best of your
ability and experience, and to the reasonable satisfaction of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Outside Activities; Non-Interference; Conflicts of Interest</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Subject to the separations contained in Attachment
4, during the term of your employment, you agree to devote your business time, attention, skill, and efforts to the business of the Company.
All benefits, profits, results, and work product arising from or incident to your services shall belong exclusively to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Except as expressly disclosed herein or
approved in advance in writing by the CEO, you shall not render commercial or professional services of any nature to any other
person or organization, whether or not for compensation, nor shall you directly or indirectly engage in or participate in any
business that is competitive with the business of the Company. The Company acknowledges and expressly approves your continued
appointment with QIMR Berghofer Medical Research Institute (&ldquo;QIMR&rdquo;). Your services to QIMR shall be conducted
independently of your employment with Kazia and outside the scope of your duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">For the avoidance of doubt: All intellectual property,
know-how, data, materials, and inventions conceived, developed, or reduced to practice solely in the course of your work for QIMR, without
use of Kazia&rsquo;s confidential information, resources, or time, shall remain the property of QIMR (or as otherwise governed by your
arrangements with QIMR). Kazia acknowledges the IP Separation list shown at Attachment 4 and agrees that the Employee is responsible for
maintaining the separation of IP and potential conflict of duties as contained in this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Conversely, all intellectual property, know-how,
data, materials, and inventions conceived, developed, or reduced to practice in the course of your employment with Kazia, or using Kazia&rsquo;s
confidential information or resources, shall be the exclusive property of Kazia subject to the separations contained in Attachment 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">The parties agree that Attachment 4 will be continuously
maintained to allow the employee to maintain appropriate separation of activities, information, and resources between the two roles to
avoid conflicts of interest and to protect the confidentiality and proprietary rights of each organization. The Company warrants that
it approves (after request and approval from CEO) of the Employee providing the contents of Attachment 4 to QIMR on request and are under
confidentiality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Nothing in this agreement prohibits you from accepting
occasional speaking or presentation engagements for customary honoraria or from serving on the boards of charitable or non-profit organizations,
provided such activities do not interfere with your duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>Travel and Expenses</U>. You acknowledge that
the nature of the position may require frequent travel within and outside of the United States from time to time. The Company will make
reasonable efforts to accommodate your circumstances and preferences in directing such travel. You will be entitled to reimbursement of
reasonable and customary expenses incurred in carrying out the position, in accordance with the Company&rsquo;s policies, on submission
of an expense report and valid receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Salary</U>. Your compensation will be as itemised
in Attachment 1 of this letter and paid to you once per month pursuant to the Company&rsquo;s regular payroll policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Performance and Salary Review</U>. Your performance
and compensation package will be reviewed no less than once annually. Any pay adjustments will be made in accordance with your performance
and in reference to industry compensation benchmarks for comparable positions. Adjustments to compensation will be at Kazia&rsquo;s sole
discretion and are not guaranteed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Sole Consideration</U>. You acknowledge that
the compensation described in Attachment 1 of this letter will be your only remuneration for your employment with the company. Kazia may
require you to provide services and / or to hold offices within the Company or on behalf of the Company without additional remuneration.
You will be required to work such hours as are reasonably required for the position, without additional payment for overtime or travel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Equity Participation</U>. Following your commencement,
Kazia will recommend to the Board of Directors that you be granted options over the company&rsquo;s stock, to an amount as specified in
Attachment 1 of this letter. This grant is at the discretion of the Board of Directors and will be subject to the company&rsquo;s Employee
Stock Option Plan. At the discretion of the Board of Directors, you may be eligible for further grants of stock options during the term
of your employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">In recognition of your unique scientific know-how,
technologies and scientific concepts that have been developed prior to your employment that could contribute to the development of new
platforms derived from such expertise, you shall be eligible to receive additional equity awards. Events or milestones that may trigger
consideration of an additional equity award include, without limitation: Execution of a material third-party license, collaboration, or
other strategic transaction relating primarily to such formation of a subsidiary, spin-out, joint venture, or similar corporate structure
established primarily to advance or commercialize any future business concept ; or achievement of another comparable strategic, value-creating
milestone relating as determined by the Board in its reasonable discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Upon the achievement, and subject to Board confirmation
that such milestone has been satisfied, the Company may grant you an equity award under the Company&rsquo;s equity incentive plan. The
size of any such award shall be determined by the Board in its reasonable discretion; provided, however, that the aggregate equity granted
to you pursuant to this Section shall not exceed [1.0%] of the Company&rsquo;s fully diluted ordinary shares outstanding as of the applicable
grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">All such awards shall be granted at fair market
value on the date of grant, subject to the Company&rsquo;s equity incentive plan and vest pursuant to a schedule determined by the Board
at the time of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Benefits</U>. Your benefits will be as itemised
in Attachment 1 of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>Vacation and Holidays</U>. You will be eligible
for paid time off (PTO) as itemised in Attachment 1 of this letter. You will also receive paid time off for Australian holidays observed
by Kazia. Kazia&rsquo;s policies regarding vacation and holidays will be provided to you separately on commencement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>Terms of Employment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Termination Notice</U> notwithstanding any
other obligation herein, your employment with the Company can be terminated by either party providing the other with the greater of two
(2) weeks notice or the amount of time prescribed in the Australian National Employment Standards (NES).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Debarment and Suspension</U>. You agree,
assert, and affirm that you are in compliance with United States Federal Executive Order 12549 &ldquo;Debarment and
Suspension&rdquo; and in further compliance with Executive Order 12689, and with Section 2455 of the Federal Acquisition Regulation
as provided in 45 CFR 76 &quot;Government-Wide Debarment and Suspension (Non-procurement) and Government-Wide Requirements for
Drug-Free Workplace (Grants)&quot;, and in further compliance with Office of Management and Budget Memorandum M-87-32,
&quot;Certification of Non-delinquency by Applicants for Federal Assistance,&quot; that I, to the best of my knowledge and
belief:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>Am not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded by any Federal department
or agency;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>Have not within a three-year period preceding the Start Date been convicted of or had a civil judgment rendered against me for commission
of fraud or a criminal offense in connection with obtaining, attempting to obtain, or performing a public (Federal, State, or local) transaction
or contract under a public transaction; violation of Federal or State antitrust statutes or commission of embezzlement, theft, forgery,
bribery, falsification or destruction of records, making false statements, or receiving stolen property;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>Am not presently indicted for or otherwise criminally or civilly charged by a governmental entity (Federal, State, or local) with
commission of any of the offenses enumerated in paragraph (1)(b) of this certification;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>Have not within a three-year period preceding the Start Date had one or more public transactions (Federal, State, or local) terminated
for cause or default; and (e) Am not currently delinquent on the repayment of any federal debt.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Confidentiality</U>. You agree that, by executing
this letter, you enter into a Confidentiality Agreement with the company, which is provided in Attachment 2 of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Work Product Agreement</U>. You agree that,
by executing this letter, you enter into a Proprietary Information and Inventions Agreement with the company, which is provided in Attachment
3 of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Notification of Material Changes</U>. You agree
to promptly notify Kazia of any material changes in your circumstances, including without limitation your residential address, your qualifications,
professional memberships or certifications, or any of the representations and warranties contained in this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Adherence to Policies</U>. You acknowledge
that you are expected act as a role model for the company and to uphold and champion its policies including, but not limited to, its policies
relating to work health and safety, equal employment opportunities, anti-discrimination, harassment and bullying. You must also comply
with any policies issued by the company, including policies relating to corporate governance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Surveillance and Data Privacy</U>. The company
undertakes continuous and ongoing surveillance in relation to activities carried out on its premises, or using its property, in order
to ensure that its workplaces are safe, and free of risk of harm to all employees and visitors, and also to protect the company&rsquo;s
business interests. In accepting employment with the company, you acknowledge the surveillance set out in this clause, and consent to
such use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Ownership of Physical Property</U>. All document,
apparatus, equipment and other physical property in any form furnished to you by the Company or produced by you or others in connection
with your employment shall be and remain the sole property of the Company. You shall return to the Company all such documents, materials
and property as and when requested by the Company, except only (i) personal copies of records relating to my compensation; (ii) if applicable,
personal copies of any materials evidencing shares of the Company&rsquo;s capital stock purchased by you and/or options to purchase shares
of the Company&rsquo;s capital stock granted to you; (iii) your copy of this Agreement and (iv) your personal property and personal documents
that you bring with you to the Company and any personal correspondence and personal materials that you accumulate and keep at the Company&rsquo;s
office during your employment. Even if the Company does not so request, you shall return all such documents, materials and property upon
termination of your employment, and, except for your personal documents, you will not take with you any such documents, material or property
or any reproduction thereof upon such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Obligations at Termination</U>. Upon termination
of your employment for any reason, you must, at the Company&rsquo;s request, cooperate with the company and render all reasonable assistance
in the prosecution or defence of legal claims and proceedings. You must execute all documents and give all reasonable assistance required
to relinquish any offices held on behalf of the Company, and to allow the Company to protect intellectual property and confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Non-Solicitation</U>. During your employment,
and for a period of twelve (12) months after termination, you may not directly or indirectly solicit, induce, recruit or encourage any
of the Company&rsquo;s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing, either
for yourself or any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Conditions of Employment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Proof of Right to Work</U>. For purposes of
federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment
in the United States. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment
relationship with you may be terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Background and Credit Review</U>. You agree
to and will promptly complete any necessary documentation to allow a personal background and credit review. All information will be held
strictly confidential but will be used to finally qualify you for this position. Satisfactory passage of this check must be completed
within seven (7) business days of your date of hire, or our employment relationship with you may be terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Warranties</U>. In accepting this offer of
employment, you warrant that:-</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">(a)</TD><TD STYLE="text-align: left">You will not be in breach of any agreement with, or obligation owed to, any third party; and</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">(b)</TD><TD STYLE="text-align: left">You have disclosed all material information to Kazia which may be relevant to the company&rsquo;s decision to offer you employment;
and</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">(c)</TD><TD STYLE="text-align: left">Any representations you have made as to your qualifications, skills, experience, industry knowledge, business influence, contacts,
and employment history are true and correct and complete.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">We are all delighted to be able to extend you
this offer and look forward to working with you. To indicate your acceptance of the Company's offer, please sign and date this letter
in the space provided below, and separately on Attachment 2 and Attachment 3. Please return the signed documents to the company. This
letter, together with its Attachments, set forth the terms of your employment with the Company and supersede any prior representations
or agreements, whether written or oral. This letter may not be modified or amended except by a written agreement, signed by the Company
and by you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Yours sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 40%">Executed by Kazia Therapeutics Limited:</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom">/s/ John E Friend II</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">Signature</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom">John E Friend II</TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Director</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Accepted and agreed by:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Dr. Sudha Rao</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1.5pt">Dr. Sudha Rao</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>Date: 4/10/26</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 218.85pt 0pt 0; text-align: right; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">ATTACHMENT 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">PARTICULARS OF EMPLOYMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; width: 30%; border: black 1pt solid">Position </TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 70%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">Chief Scientific Officer </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">Position Overview </TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The Chief Scientific Officer (CSO) is responsible
    for the scientific vision, strategy, and execution across Kazia Therapeutics&rsquo; oncology portfolio. The CSO will provide strategic
    leadership for translational science, early clinical development strategy, biomarker integration, and external scientific engagement,
    ensuring that Kazia&rsquo;s programs are scientifically differentiated, clinically compelling, and positioned to maximize regulatory,
    partnering, and acquisition value.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">This role is both hands-on and strategic, requiring
    deep R&amp;D oncology expertise, credibility with regulators and key opinion leaders, and the ability to translate complex science into
    clear, value-driven narratives for internal decision-making, partners, and investors.</P></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">Manager </TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid">CEO </TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">Place of Work </TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid">Home-based and office based </TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">Commencement Date </TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid">April 13, 2026 </TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">Base Salary </TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid">AUD$ 325,000 per annum (paid as $27083 per calendar month) based on 3 days/week </TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">Target Bonus </TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid">40% of your annual base salary </TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">LTI Options Grant</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(subject to Board approval)</P></TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid">250,000 (two hundred fifty thousand) ADS options to vest in 2 subsequent equal annual instalments, beginning on the Commencement Date &nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">SUPERANNUATION </TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid">In accordance with the Superannuation Guarantee Administration Act 1992 (Cth)</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">Paid Time Off (PTO) </TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify">12 days per calendar year (prorated for 3days/week) </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">ATTACHMENT 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">CONFIDENTIALITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">For the purposes of this Agreement, Confidential
Information means information which came to the employee&rsquo;s knowledge in the course of, or as a result of, their employment including,
but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.6pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD><FONT STYLE="font-size: 10pt">the business or affairs, financial information,
                                            intellectual property, business plans, research and development, and sales and marketing
                                            information of the Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.6pt"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD><FONT STYLE="font-size: 10pt">unpatented molecular structures, manufacturing
                                            processes, assay methodologies, preclinical or clinical data;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.6pt"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD><FONT STYLE="font-size: 10pt">information which would reasonably be
                                            considered to be of a business sensitive nature;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.6pt"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD><FONT STYLE="font-size: 10pt">trade secrets and confidential information
                                            and know-how of the Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.6pt"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD><FONT STYLE="font-size: 10pt">information regarding investments, investment
                                            opportunities, investment strategies and investment research of the Company; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.6pt">(f)</TD><TD>confidential information of a third party that has been shared with Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Confidential Information will not include information
which is or becomes readily available in the public domain otherwise than as a result of the breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">The employee must not use or disclose this Confidential
Information during and after their employment, and must take all reasonable steps to prevent the unauthorised disclosure of the Confidential
Information, except in the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.6pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="padding-right: 13.3pt"><FONT STYLE="font-size: 10pt">the Company
                                            has given its prior written consent; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.55pt"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="padding-right: 13.3pt"><FONT STYLE="font-size: 10pt">in the
                                            proper course of performing their duties and for the benefit of the Company; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.55pt"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="padding-right: 13.3pt"><FONT STYLE="font-size: 10pt">to the
                                            extent required by law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Without limiting the generality of the above,
the employee must not disclose Confidential Information to other employees of the Company unless these employees are authorised by the
Company to receive this information and need to know this information to perform their duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">The employee must immediately notify the Company
if the employee suspects or becomes aware that Confidential Information has been improperly used, copied or disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">The employee must not copy or remove from the
Company&rsquo;s premises any document which contains Confidential Information except for the purpose of properly performing the duties
of the position and for the benefit of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">The employee must provide assistance reasonably
requested by the Company in relation to proceedings against any person for unauthorised use, copying or disclosure of Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Accepted and agreed by:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Dr. Sudha Rao</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1.5pt">Name: Dr. Sudha Rao</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>Date: 4/10/26</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">ATTACHMENT 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Subject to Attachment 4 in exchange for the Employee
becoming employed by the Company, or any of its current or future subsidiaries, affiliates, successors or assigns (collectively, the &ldquo;Company/Kazia&rdquo;),
and for any cash and equity compensation for the Employee&rsquo;s services, I hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Assignment of Inventions.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Without
                                            further compensation, I hereby agree promptly to disclose to the Company, all Inventions
                                            (as defined below) which I may solely or jointly develop or reduce to practice during the
                                            period of my employment or consulting relationship with the Company which:</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(i)
                                            pertain to any line of business activity of the Company,</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(ii)
                                            are aided by the use of time, material or facilities of the Company, whether or not during
                                            working hours or</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(iii)
                                            relate to any of my work during the period of my employment or consulting relationship with
                                            the Company, whether or not during normal working hours (&ldquo;Company Inventions&rdquo;).</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">During
                                            the term of my employment or consultancy, all Company Inventions that I conceive, reduce
                                            to practice, develop or have developed (in whole or in part, either alone or jointly with
                                            others) shall be the sole property of the Company and its assigns to the maximum extent permitted
                                            by law (and to the fullest extent permitted by law shall be deemed &ldquo;works made for
                                            hire&rdquo;), and the Company and its assigns shall be the sole owner of all patents, copyrights,
                                            trademarks, trade secrets and other rights in connection therewith. I hereby assign to the
                                            Company any rights that I may have or acquire in such Company Inventions.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(f)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">I
                                            have provided to the Company, prior to my engagement, a complete list of all Inventions,
                                            if any, made by me prior to my employment or consulting relationship with the Company that
                                            are relevant to the Company&rsquo;s business, and I represent a</FONT>nd warrant that such
                                            list is complete. If no such list is provided, I represent that I have no such Inventions
                                            at the time of signing this Agreement. If in the course of my employment or consultancy (as
                                            the case may be) with the Company, I use or incorporate any Invention in which I have an
                                            interest into a product or process of the Company, the Company is hereby granted a nonexclusive,
                                            fully paid-up, royalty-free, perpetual, irrevocable worldwide license of my interest to use
                                            and sublicense such Invention without restriction of any kind.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">NOTICE REQUIRED BY REVISED CODE OF WASHINGTON
49.44.140:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Any assignment of Inventions required by this
Agreement does not apply to an Invention for which no equipment, supplies, facility or trade secret information of the Company was used
and which was developed entirely on the employee&rsquo;s own time, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">(a) the Invention relates(i) directly to the business
of the Company or (ii) to the Company&rsquo;s actual or demonstrably anticipated research or development or (b) the Invention results
from any work performed by the employee for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Further Assistance and Power of Attorney</U>.
I agree to perform, during and after my employment or consulting relationship, all acts deemed necessary or desirable by the Company to
permit and assist it, at its expense, in obtaining and enforcing the full benefits, enjoyment, rights and title throughout the world in
the Inventions assigned to the Company as set forth in Section 4 above. Such acts may include, but are not limited to, execution of documents
and assistance or cooperation in legal proceedings. I hereby irrevocably designate the Company and its duly authorized officers and agents
as my agent and attorney-in fact, to execute and file on my behalf any such applications and to do all other lawful acts to further the
prosecution and issuance of patents, copyright and mask work registrations related to such Inventions. This power of attorney shall not
be affected by my subsequent incapacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Inventions</U>. As used in this Agreement,
the term &ldquo;Inventions&rdquo; means discoveries, developments, concepts, designs, ideas, know how, improvements, inventions, trade
secrets and/or original works of authorship, whether or not patentable, copyrightable or otherwise legally protectable. This includes,
but is not limited to, any new product, machine, article of manufacture, biological material, method, procedure, process, technique, use,
equipment, device, apparatus, system, compound, formulation, composition of matter, design or configuration of any kind, or any improvement
thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Survival</U>. This Agreement (a) shall survive
for a period of five years beyond the termination of my employment by or consulting relationship with the Company, (b) inures to the benefit
of successors and assigns of the Company and (c) is binding upon my heirs and legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><U>Injunctive Relief</U>. I acknowledge that violation
of this Agreement by me may cause irreparable injury to the Company, and I agree that the Company will be entitled to seek extraordinary
relief in court, including, but not limited to, temporary restraining orders, preliminary injunctions and permanent injunctions without
the necessity of posting a bond or other security and without prejudice to any other rights and remedies that the Company may have for
a breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">Accepted and agreed by:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-indent: 1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Dr. Sudha Rao</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1.5pt">Name: Dr. Sudha Rao</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>Date: 4/10/26</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="text-transform: uppercase">Attachment
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="text-transform: uppercase">IP
Separation list &ndash; QMIR and Kazia</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">The Parties acknowledge and agree that
because the employee is also to be employed by QIMR on a permanent part-time basis for two (2) days per week that the employee will maintain
the following separation of duties described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">For the avoidance
of doubt: All intellectual property, know-how, data, materials, and inventions conceived, developed, or reduced to practice solely in
the course of work for QIMRb, without use of Kazia&rsquo;s confidential information, resources, or time, shall remain the property of
QIMRb (or as otherwise governed by the arrangements with QIMRb). The employee is responsible for maintaining the separation of IP and
potential conflict of duties as contained in this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">Conversely, all
intellectual property, know-how, data, materials, and inventions conceived, developed, or reduced to practice in the course of your employment
with Kazia, or using Kazia&rsquo;s confidential information or resources, shall be the exclusive property of Kazia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">The parties agree
that Attachment 4 will be continuously maintained to allow the employee to maintain appropriate separation of activities, information,
and resources between the two roles to avoid conflicts of interest and to protect the confidentiality and proprietary rights of each organization.
The Company warrants that it approves after request and approval from CEO of the Employee providing the contents of Attachment 4 to QIMR
on request and are under confidentiality. The following programs are Kazia related programs, platforms and assets:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt"><B>Program PI3K-mTOR
PROGRAM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">All activities
focused around PI3K-mTOR pathway inhibitors, including Paxalisib. This will involve all current and future Intellectual property (IP),
biomarker for liquid biopsy analysis for immune analysis and novel targeting approaches,.pre-clinical and clinical work and advancement
to clinical trials across all indications. All PI3K-mTOR biomarker (including but not limited to CTC, CTC cluster, liquid biopsy, cancer
cell phenotype, immune repertoire and memory, viral mimicry) associated work for patient stratification will be carried out within this
program. All inventions and patent related documents arising from this program, for example, expansion of the Paxalisib program to other
clinical indications patient sub-groups will form part of this work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt"><B>LICENSED PATENT
RIGHTS</B> Application No. Filing Date Jurisdiction Title No. 2022903523 21 November 2022 Australia Patent Application PI3K COMBINATION
No. 2024900337 13 February 2024 Australia Patent Application Prognostic signature</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt"><B>Program SETDB1
: Immunotherapy targeting program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">All activities
within the SETDB1 program drug development to the clinic and biomarker liquid biopsy platform development for patient stratification,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Licensed Patent Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">MSETC form PCT/AU2023/011289
titled &ldquo;NOVEL INHIBITORS OF HISTONE METHYLTRANSFERASE NUCLEAR LOCALISATION&rdquo; currently in National Phase in the following
regions</FONT>:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border: Black 1pt solid; width: 50%">Region</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%">Patent Application Number</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">United States</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">18/992,665</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Canada</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">3,260,139</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Australia</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">2023307414</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">New Zealand</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">818692</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Israel</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">318247</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">South Africa</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">2025/01339</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Singapore</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">11202409229X</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Europe</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">23 838 337.6</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">India</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">202517012154</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Republic of Korea</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">10-2025-7004792</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Malaysia</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">PI2025000103</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Japan</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">2025-501325</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">China</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">202380058023.5</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Brazil</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">BR 11 2025 000517 0</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Mexico</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">MX/A/2025/000539</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Russia</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">2025103099</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Indonesia</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">P-0020250132</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><B>Program PDL1 Protein Degrader :
Immunotherapy targeting program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: left; text-indent: -0.5pt">All activities
within the PDL1 Protein Degrader program drug development to the clinic and biomarker liquid biopsy platform development for patient stratification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><B>Licensed Patent
Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">NDL2 &amp; other formulations Retro-reverso form PCT/AU2022/050023 titled &ldquo;NOVEL BICYCLIC PEPTIDES&rdquo; currently in National
Phase in the following regions:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border: Black 1pt solid; width: 50%">Region</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%">Patent Application Number</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">United States</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">18/273200</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Canada</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">3208598</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Australia</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">2022209878</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">New Zealand</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">802841</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Israel</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">304545</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">South Africa</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">2023/08030</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Singapore</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">11202305518P</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Europe</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">22741955.3</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">India</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">202317048538</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Republic of Korea</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">10-2023-7027582</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Malaysia</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">PI2023002121</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Japan</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">2023-543460</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">China</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">202280022296.X</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 11</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B><A NAME="ab_002"></A>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Kazia Therapeutics Strengthens Scientific Leadership with Appointment
of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sydney, Australia &ndash; April 15, 2026</B> &ndash; Kazia Therapeutics
(NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced
the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Rao is the scientific originator of the epigenetic framework underlying
paxalisib and a pioneer in next-generation therapeutic platforms, including PD-L1 protein degradation and SETDB1-targeted chromatin modulation.
Her appointment brings deep expertise in translational epigenetics, AI-guided epi-drug discovery capability, liquid and spatial epigenetic
clinical biomarker precision medicine platforms, and early clinical development into Kazia&rsquo;s executive leadership as the Company
advances its integrated oncology platform strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Rao is a highly accomplished translational scientist and biotech
executive with more than 20 years of experience spanning pharmaceutical R&amp;D, biotechnology, and early clinical development. She currently
holds a professorial appointment and leads the Gene Regulation and Translational Medicine Laboratory at QIMR Berghofer Medical Research
Institute and previously held senior scientific roles at Sanofi/Rh&ocirc;ne-Poulenc in the UK, where she contributed to one of the earliest
clinical genomics platforms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">She is the founder and former Chief Scientific Officer of EpiAxis Therapeutics
and has advanced first-in-class epigenetic therapeutics from discovery through IND-enabling studies and into early clinical trials, including
the first Phase 1b study of an LSD1 inhibitor in metastatic breast cancer. Dr. Rao is lead inventor on 39 international patents and has
authored numerous high-impact publications in journals including <I>Science</I>, <I>Nature</I>, and <I>Immunity</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At Kazia, Dr. Rao will lead all research and development activities,
advancing the Company&rsquo;s pipeline and expanding its next-generation platform capabilities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor being developed across oncology indications, including advanced breast cancer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt"></FONT>&#9679;</TD><TD>NDL2, a novel PD-L1 protein degrader platform designed to target intracellular and nuclear PD-L1 biology; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>MSETC, a first-in-class SETDB1-targeted epigenetic program aimed at reversing immune evasion at the chromatin level.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Her scientific work has been central to advancing the concept of PI3K/mTOR
inhibition as a driver of epigenetic reprogramming, forming the foundation of Kazia&rsquo;s strategy to move beyond pathway inhibition
toward therapeutic control of cancer&rsquo;s regulatory drivers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. John Friend, CEO of Kazia Therapeutics, commented: &ldquo;Dr. Rao
is a leading translational epigenetics scientist, a breast cancer researcher, and the lead inventor behind the intellectual property linking
PI3K/mTOR inhibition to epigenetic regulation. As the architect of much of our platform, including paxalisib, NDL2, and MSETC, her appointment
allows us to immediately strengthen execution while advancing a more integrated, platform-driven oncology strategy.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I am excited by the opportunity to advance a next-generation
oncology platform at Kazia. PI3K/mTOR is a key driver of tumour growth and a master regulator of epigenetic programs that shape tumour
behaviour, the tumour microenvironment (TME), and immune evasion,&rdquo; stated Dr. Rao. &ldquo;We are building a platform focused on
precision targeting and precision medicine, integrating spatial and liquid epigenomics and AI-driven drug discovery to accelerate novel
therapies. This includes paxalisib alongside emerging programs such as the PD-L1 degrader and SETDB1-targeting approaches. We aim to enable
patient selection, real-time target engagement, and a scalable pipeline with clear clinical translation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Rao will also play a key role in advancing Kazia&rsquo;s biomarker
strategy, external collaborations, scientific publications, and strategic partnerships, while continuing to expand the Company&rsquo;s
platform and pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Kazia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug
development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K
/ Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or
has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024,
and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical
trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous
system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation
for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by
the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway
mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug
Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and
July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April
2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class nuclear PD-L1 protein degrader
program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, currently in preclinical development.
For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This announcement may contain forward-looking statements, which can
generally be identified as such by the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;estimate,&rdquo; &ldquo;future,&rdquo;
&ldquo;forward,&rdquo; &ldquo;anticipate,&rdquo; or other similar words. Any statement describing Kazia&rsquo;s future plans, strategies, intentions,
expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements,
including, but not limited to, statements regarding: the anticipated contributions of Dr. Sudha Rao as Chief Scientific Officer; expectations
regarding Dr. Rao&rsquo;s leadership of Kazia&rsquo;s research and development activities; the potential of Kazia&rsquo;s three-platform
oncology strategy, including paxalisib, NDL2, and MSETC; expectations regarding the advancement of Kazia&rsquo;s pipeline and platform
capabilities; the potential of paxalisib, including in advanced breast cancer and other oncology indications; the potential of NDL2 as
a PD-L1 protein degrader platform; the potential of MSETC as a SETDB1-targeted epigenetic program; expectations regarding Kazia&rsquo;s
biomarker strategy, AI-driven drug discovery, and precision medicine capabilities; and Kazia&rsquo;s broader pipeline strategy and anticipated
benefits of its integrated platform approach. Such statements are based on Kazia&rsquo;s current expectations and projections about future events
and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ
materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with: the ability to
attract and retain key personnel, including Dr. Rao; the development of early-stage therapeutic programs; the risk that preclinical results
may not be predictive of clinical results; risks related to regulatory approvals; risks related to Kazia&rsquo;s reliance on third-party collaborators;
risks related to intellectual property protection; risks related to the impact of global economic conditions; and risks related to Kazia&rsquo;s
ability to maintain compliance with the applicable NASDAQ continued listing requirements and standards. These and other risks and uncertainties
are described more fully in Kazia&rsquo;s Annual Report on Form 20-F filed with the SEC, and in subsequent filings with the United States Securities
and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements,
which apply only as of the date of this announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea028633402_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028633402_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ ,0# 2(  A$! Q$!_\0
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028633402_ex10-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028633402_ex10-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ -8# 2(  A$! Q$!_\0
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MTZ]'#XF,.>>'A6I3G2JSIZJ:I5*G+9\VJ+=%0-*P4E4#'#X!8JI92H52P1B
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M,F,,R*K"7D/^#??6?VG/V?OCC\5/V9?BI\'?BUX2^'7Q0BUOQ'IVL:_X-O\
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4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
